
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension
The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests
Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens
The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity
Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.
SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.
Investigators reported the oral therapy was well-tolerated in trials for early treatment of non-proliferative diabetic retinopathy and associated oedema
The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD
In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained
Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40
Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption
A new functional classification can help achieve precise vision goals
With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.
The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.
Johann Krüger, MD, shares insights from 26 years of experience
The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050
The framework covers ocular hypertension to severe progression
Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers
The Tecnis Odyssey, launched in the US in October 2024, is now available in Europe, the Middle East and Canada